TELA Bio (TELA)

• Market cap: $37.8M
• 1 day: -0.09%
• 5 days: 3.73%
• 1 month: -60.65%
• 3 months: -64.45%
• 6 months: -61.60%
• Year to date: -66.80%
• 1 year: -81.50%
• 5 years: -87.94%
• 10 years: -92.84%
• Sector: Healthcare
• Industry: Medical Devices

About: TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Employees: 209

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

227,500% more call options, than puts

Call options by funds: $2.28M | Put options by funds: $1K

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

79% more capital invested

Capital invested by funds: $45.6M [Q3] → $81.6M (+$36.1M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

4% less funds holding

Funds holding: 49 [Q3] → 47 (-2) [Q4]

4.27% less ownership

Funds ownership: 72.89% [Q3] → 68.63% (-4.27%) [Q4]

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 109% upside
• Avg. target: $5.33 458% upside
• High target: $7 632% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin 14% 1-year accuracy 2 / 14 met price target	632% upside $7	Buy Maintained	21 Mar 2025
Citizens Capital Markets David Turkaly 30% 1-year accuracy 8 / 27 met price target	632% upside $7	Market Outperform Maintained	21 Mar 2025
Piper Sandler Matt O'Brien 32% 1-year accuracy 16 / 50 met price target	109% upside $2	Neutral Downgraded	21 Mar 2025